Garrett, Joan T <br/><br/>
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.  [electronic resource] 

 -  Cancer research  Oct 2013 
 - 6013-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-13-1191  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Breast Neoplasms--metabolism<br/>Cell Proliferation--drug effects<br/>Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors<br/>Female<br/>Humans<br/>Immunoblotting<br/>Immunoprecipitation<br/>Lapatinib<br/>Mice<br/>Phosphorylation--drug effects<br/>Protein Multimerization--drug effects<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Quinazolines--pharmacology<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Receptor, ErbB-3--antagonists & inhibitors<br/>Signal Transduction<br/>Survival Rate<br/>Trastuzumab<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays